Amarin (NASDAQ:AMRN - Get Free Report) was downgraded by Wall Street Zen from a "buy" rating to a "hold" rating in a report issued on Sunday, Wall Street Zen reports.
Other research analysts have also recently issued research reports about the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Amarin in a research report on Thursday, October 15th. JPMorgan Chase & Co. initiated coverage on shares of Amarin in a research note on Friday, August 21st. They issued an "underweight" rating and a $13.00 price target on the stock. Finally, Zacks Research downgraded shares of Amarin from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, November 3rd. One analyst has rated the stock with a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Sell" and a consensus target price of $13.00.
View Our Latest Research Report on AMRN
Amarin Stock Up 0.3%
NASDAQ:AMRN opened at $11.61 on Friday. The firm has a 50-day moving average price of $12.75 and a 200 day moving average price of $14.24. The firm has a market capitalization of $245.20 million, a PE ratio of -12.09 and a beta of 0.81. Amarin has a 12-month low of $11.25 and a 12-month high of $17.31.
Amarin (NASDAQ:AMRN - Get Free Report) last announced its earnings results on Wednesday, October 28th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.11. The company had revenue of $39.55 million for the quarter, compared to analyst estimates of $43.76 million. Amarin had a negative return on equity of 0.52% and a negative net margin of 10.87%. On average, research analysts expect that Amarin will post -0.85 EPS for the current year.
Institutional Investors Weigh In On Amarin
A number of large investors have recently added to or reduced their stakes in AMRN. R Squared Ltd raised its holdings in Amarin by 190.9% in the 3rd quarter. R Squared Ltd now owns 49,272 shares of the biopharmaceutical company's stock valued at $641,000 after acquiring an additional 32,334 shares in the last quarter. Brooklands Fund Management Ltd grew its holdings in shares of Amarin by 23.1% during the 3rd quarter. Brooklands Fund Management Ltd now owns 218,373 shares of the biopharmaceutical company's stock worth $2,839,000 after purchasing an additional 41,048 shares in the last quarter. Crossmark Global Holdings Inc. bought a new position in shares of Amarin in the third quarter worth $146,000. LCM Capital Management Inc increased its position in shares of Amarin by 17.1% in the third quarter. LCM Capital Management Inc now owns 60,162 shares of the biopharmaceutical company's stock worth $782,000 after purchasing an additional 8,800 shares during the period. Finally, GAMMA Investing LLC increased its position in shares of Amarin by 197.4% in the second quarter. GAMMA Investing LLC now owns 1,576 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 1,046 shares during the period. Institutional investors and hedge funds own 22.25% of the company's stock.
About Amarin
(
Get Free Report)
Amarin Corporation plc is a biopharmaceutical company focused on developing and commercializing therapies intended to reduce cardiovascular risk. Its principal product is VASCEPA (icosapent ethyl), a prescription omega-3 fatty-acid medicine derived from highly purified eicosapentaenoic acid.
VASCEPA was initially approved in the United States to help lower triglyceride levels in certain patients and later received expanded approval to reduce the risk of cardiovascular events in eligible adults with elevated cardiovascular risk.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amarin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amarin wasn't on the list.
While Amarin currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.